BIOVAXYS TECHNOLOGY CORP by BioVaxys Technology Corp. (BVAXF)

About BIOVAXYS TECHNOLOGY CORP by BioVaxys Technology Corp. (BVAXF)

BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.

BIOVAXYS TECHNOLOGY CORP by BioVaxys Technology Corp. News